Neomycin — How Dangerous It Is, Side Effects and Hearing Loss

EFFECTIVE | TOXIC

What names is neomycin sold under

The international nonproprietary name is neomycin, Neomycin. In medicinal products, neomycin sulfate, Neomycin sulfate, is most commonly used. The pharmaceutical substance is a sulfate complex of neomycin B and neomycin C produced by Streptomyces fradiae. The term framycetin refers primarily to neomycin B and is not a fully interchangeable name for the entire neomycin B and C complex. Neomycin should also not be confused with gentamicin, amikacin, tobramycin, or kanamycin: these are other aminoglycosides, although their organ toxicity may be additive.

Neomycin is found in tablets and powders for oral administration, skin ointments, creams and aerosols, ophthalmic ointments and drops, and otic solutions and suspensions. Injectable forms are virtually no longer used in modern clinical practice because of pronounced systemic toxicity. Specific product names depend on the country and manufacturer: Neomycin Sulfate, Неомицина сульфат, Neosporin, Cortisporin, Maxitrol, and others. The presence of a brand name does not guarantee that a patient will immediately recognize neomycin among the ingredients.

Hidden duplication is particularly likely when several combination products are used at the same time. Neomycin may be included in products containing polymyxin B, bacitracin, gramicidin, hydrocortisone, dexamethasone, local anesthetics, and other components. A patient may simultaneously apply a skin ointment, use eye drops, and instill ear drops, effectively receiving the same active substance from several sources. Examples of common combinations include neomycin + polymyxin B + hydrocortisone, neomycin + polymyxin B + bacitracin, neomycin + polymyxin B + dexamethasone.

Why neomycin is considered harmless and where the real risk begins

Neomycin is often perceived as an “ordinary topical antibiotic” that can be used on any scratch, weeping dermatitis, runny nose, earache, or eye inflammation. The real risk begins when the product is used without confirming the bacterial nature of the condition, applied to damaged tissues, used repeatedly, or combined with other nephrotoxic and ototoxic drugs.

Neomycin can cause nephrotoxicity, neurotoxicity, irreversible bilateral sensorineural hearing loss, and neuromuscular blockade with respiratory depression. These complications have been reported even with oral use at recommended doses. The absence of immediate symptoms does not exclude injury: cochlear toxicity is often delayed and may become apparent only after damage to structures of the eighth cranial nerve has already occurred.

When taken orally, approximately 97% of the drug remains in the intestine and is excreted in the feces, but the small absorbed fraction is distributed into tissues and eliminated by the kidneys. Its elimination is slowed in renal dysfunction. Systemic absorption increases substantially when the intestinal mucosa is inflamed or ulcerated and when the drug is applied to burns, large wound surfaces, surgical cavities, or damaged mucous membranes. The official prescribing information describes irreversible deafness, renal failure, and death due to neuromuscular blockade after local irrigation of surgical fields with even small amounts of the drug.

Self-treatment with ear drops without otoscopy is particularly dangerous. If the tympanic membrane is perforated, neomycin can reach the middle ear and damage the hair cells of the organ of Corti. For the combination of neomycin with polymyxin B and hydrocortisone, the official prescribing information specifically states that the product must not be used with a perforated tympanic membrane and that treatment is limited to ten consecutive days.

Side effects after the first dose and a short course

When taken orally, the most common reactions are nausea, vomiting, and diarrhea. Abdominal pain and discomfort, disruption of the intestinal microbiota, and overgrowth of nonsusceptible microorganisms, including fungi, may occur. Neomycin has no activity against viral or fungal infections, so its use in such conditions is not only ineffective but may also create conditions for superinfection.

With topical use, burning, itching, dryness, redness, scaling, swelling, and allergic contact dermatitis may occur. Sensitization often develops not as a dramatic immediate allergic reaction, but as gradually worsening inflammation and failure to heal. The patient may interpret the deterioration as a persistent infection and continue applying the antibiotic even though neomycin itself has become the source of inflammation. For otic combinations, allergic sensitization is identified as the most frequently observed reaction.

Clinically significant early signs of toxicity include noise, ringing, or buzzing in the ears, a feeling of ear fullness, reduced perception of high-frequency sounds, dizziness, unsteadiness, impaired balance, paresthesias, muscle twitching, marked weakness, decreased urine output, and elevated creatinine. A patient may not associate these symptoms with a topical ointment or ear drops.

A life-threatening complication is neuromuscular blockade. It manifests as progressive muscle weakness and difficulty swallowing and breathing, potentially progressing to respiratory paralysis. The risk is particularly high when neomycin is combined with anesthetics, muscle relaxants, and massive transfusion of citrated blood.

Side effects with prolonged or repeated use

The principal cumulative risk is irreversible ototoxicity. Neomycin primarily damages the outer hair cells of the organ of Corti. High-frequency hearing is affected first, which the patient may not notice during ordinary conversation. The damage then extends into the speech-frequency range. Hearing loss is often bilateral and may continue to progress after the drug has been discontinued. The official prescribing information warns that partial or complete deafness may become apparent a considerable time after treatment has ended.

Vestibular toxicity manifests as dizziness, instability, oscillopsia, impaired coordination, and inability to walk confidently in the dark. The absence of dizziness does not exclude cochlear injury: the auditory and vestibular components of toxicity may develop independently.

Nephrotoxicity is associated with accumulation of the aminoglycoside in proximal renal tubular cells. Proteinuria, cylindruria, reduced urine specific gravity, increased urea and creatinine, a decline in estimated glomerular filtration rate, and decreased urine output may occur. A toxic cycle develops: kidney injury slows the elimination of absorbed neomycin, while increased systemic exposure further aggravates damage to the kidneys and inner ear.

Prolonged oral use can cause malabsorption syndrome. The official prescribing information states that 12 g of neomycin per day impairs the absorption of fats, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, vitamin B12, and iron. Steatorrhea, weight loss, nutritional deficiencies, and deterioration in general condition may occur.

Prolonged topical use increases the risk of contact sensitization and overgrowth of nonsusceptible bacteria and fungi. The likelihood of an allergic reaction is particularly high in chronic otitis externa, eczema, stasis dermatitis, and a damaged skin barrier. Once sensitization has developed, it may restrict future use not only of neomycin but also of some related aminoglycosides because of cross-allergy.

Tolerance, drug dependence, and a classic withdrawal syndrome are not characteristic of neomycin. However, repeated courses create a cumulative organotoxic burden, select for resistant flora, and may mask a misdiagnosed fungal, viral, or allergic disease.

Contraindications and high-risk groups

Oral neomycin is contraindicated in intestinal obstruction, hypersensitivity to the drug, and inflammatory or ulcerative diseases of the gastrointestinal tract in which systemic absorption of the antibiotic may increase. Allergy to other aminoglycosides increases the risk of a cross-reaction.

Patients with chronic kidney disease, reduced glomerular filtration rate, acute kidney injury, dehydration, or electrolyte disturbances are at increased risk of neomycin accumulation, nephrotoxicity, and hearing loss. In older adults, a normal creatinine concentration does not always indicate preserved filtration because of reduced muscle mass; therefore, creatinine clearance or glomerular filtration rate should be calculated.

Particular monitoring is required in patients with pre-existing tinnitus, hearing loss, balance disorders, previous aminoglycoside exposure, or occupational noise exposure. New symptoms may mistakenly be interpreted as a continuation of a pre-existing condition.

In myasthenia gravis, parkinsonism, and other disorders involving impaired neuromuscular transmission, neomycin can worsen muscle weakness because of its curare-like action. A severe complication is respiratory failure.

In carriers of certain mitochondrial MT-RNR1 variants, particularly m.1555A>G, severe aminoglycoside ototoxicity may develop even at drug concentrations usually considered therapeutic. A positive family history of unexplained deafness following antibiotic use warrants particular caution.

Aminoglycosides cross the placenta and may potentially damage the fetal auditory system. During pregnancy, neomycin is used only when the expected benefit convincingly outweighs the risk. For oral use in individuals under 18 years of age, safety and efficacy have not been adequately established; the official prescribing information recommends caution and limiting the duration of treatment.

Otic neomycin products are contraindicated in confirmed or suspected perforation of the tympanic membrane. Pain following trauma, surgery, barotrauma, or purulent or bloody ear discharge requires otoscopic examination before topical treatment is started.

Dangerous interactions

Concomitant or sequential use with other aminoglycosides — gentamicin, amikacin, tobramycin, kanamycin, streptomycin, and paromomycin — is highly undesirable. Their nephrotoxicity, neurotoxicity, and ototoxicity may be additive. Not only injections and tablets but also topical, ophthalmic, and otic formulations must be taken into account, especially when the tissue barrier is damaged.

Combination with vancomycin, amphotericin B, cisplatin, polymyxin B, colistin, bacitracin, and other drugs with nephrotoxic or neurotoxic potential should be avoided. The official prescribing information explicitly warns of the additive toxicity of such combinations.

Furosemide and ethacrynic acid can independently damage hearing and intensify aminoglycoside ototoxicity. Diuretics may also contribute to dehydration and impaired renal elimination of neomycin. Such a combination requires either avoiding concurrent use or strict clinical, audiological, and laboratory monitoring.

Neomycin potentiates the effects of nondepolarizing and depolarizing muscle relaxants, including tubocurarine and succinylcholine. During anesthesia, prolonged neuromuscular blockade and respiratory paralysis may occur. The anesthesiologist should be informed of recent neomycin use, including oral formulations and topical forms applied over a substantial surface area.

Oral neomycin reduces gastrointestinal absorption of penicillin V, vitamin B12, methotrexate, fluorouracil, and digoxin. When combined with digoxin, the clinical effect and drug concentration should be monitored. Neomycin may enhance the effect of coumarin anticoagulants by reducing the availability of vitamin K, thereby increasing the risk of excessive anticoagulation.

Alcohol does not produce a specific chemical reaction with neomycin comparable to a disulfiram-like effect. However, alcohol consumption in the presence of diarrhea, vomiting, and dehydration may impair renal perfusion and thereby increase toxicological risk. In severe infection, hepatic encephalopathy, or impaired renal function, alcohol is contraindicated because of the underlying condition.

Herbal diuretics and multi-ingredient herbal products must also be taken into account. They should not be combined indiscriminately with furosemide or other diuretics or used during dehydration or acute kidney injury under the pretext of “accelerating antibiotic elimination.”

Patient mistakes

The main mistake is using neomycin without a diagnosis. Redness, itching, discharge, and weeping are automatically assumed to indicate a bacterial infection, although the cause may be a fungal lesion, allergy, viral infection, eczema, irritation, or trauma. Neomycin does not treat these conditions and can aggravate some of them.

A common mistake is increasing the amount of ointment or the frequency of instillation when there is no rapid effect. Excessive topical application does not make the drug more effective, but it increases the area of exposure, sensitization, and potential absorption.

Instilling ear drops without checking the tympanic membrane is particularly dangerous. A patient cannot reliably rule out perforation without examination. Using drops after trauma, barotrauma, surgery, or in the presence of purulent discharge creates a risk of irreversible hearing damage.

Other mistakes include treating large burns and deep wounds, applying the drug under an occlusive dressing, using it longer than recommended, simultaneously using several products containing neomycin, giving the medication to other family members, using expired previously opened drops, and repeating an earlier course without a new medical examination.

With oral use, dangerous practices include self-prescribing the drug “to cleanse the intestine,” treating ordinary diarrhea, increasing the dose when there is no effect, shortening dosing intervals, continuing treatment for more than two weeks without monitoring, and ignoring reduced urine output, tinnitus, or dizziness. Officially, oral neomycin should be used at the minimum effective dose and for the shortest possible course; treatment longer than two weeks is not recommended.

Overdose and poisoning

There is no universal single toxic dose of neomycin that is equally dangerous for all patients. With oral administration, acute poisoning is less typical because absorption from an intact intestine is poor. The main threat is cumulative overdose: high daily doses, prolonged treatment, renal failure, dehydration, damaged intestinal mucosa, and combination with other organotoxic drugs.

In specific clinical situations, official oral regimens may reach 4–12 g of neomycin sulfate per day, but such doses are used only for strict indications, for a short period, and under medical supervision. A dose of 12 g per day is already associated with malabsorption syndrome. These values must not be interpreted as an everyday “safe limit”: in a patient with impaired renal function, toxicity may occur at a substantially lower cumulative exposure.

During the first hours and days, nausea, vomiting, diarrhea, paresthesias, muscle twitching, and weakness may occur. Kidney injury may initially manifest only as changes in urinalysis, an increase in creatinine, and a decrease in estimated filtration. Ototoxicity is often clinically silent: inner-ear injury may already be developing while the patient has not yet noticed any change in hearing.

Later, tinnitus, reduced perception of high-frequency sounds, bilateral hearing impairment, dizziness, unsteadiness, and oscillopsia may appear. Hearing may continue to deteriorate after the drug is discontinued. Hearing loss may be irreversible.

Severe intoxication manifests as acute renal failure, pronounced muscle weakness, impaired swallowing, respiratory depression, and respiratory paralysis. There is no specific antidote capable of restoring damaged inner-ear cells. Calcium salts and mechanical ventilation may be used in neuromuscular blockade. Neomycin can be removed from the blood by hemodialysis.

The drug must be discontinued immediately and emergency medical care sought if new hearing loss, tinnitus, severe dizziness, reduced urine output, progressive muscle weakness, difficulty swallowing, or difficulty breathing occurs. Waiting for pronounced deafness or anuria is unacceptable.

Detoxification after neomycin and a safe integrative alternative

Detoxification after antibiotics should not be understood as a mythical instant “flushing out” of the drug, but as stopping further toxic exposure, assessing target organs, restoring fluid and electrolyte balance, and supporting physiological excretion, the intestinal barrier, antioxidant systems, and tissues damaged by antibiotic therapy. Established irreversible hearing loss cannot be reversed by herbal products, sorbents, or increased diuresis.

The Metal and Xenobiotic Detoxification Complex may serve as the foundation of an integrative recovery program. The manufacturer positions it as a multi-level support product for the biotransformation and elimination of xenobiotics, including antibiotics, involving antioxidant, intestinal, hepatic, and renal mechanisms. Its listed ingredients include Thunbergia laurifolia, Tiliacora triandra, Chlorella vulgaris, Spirulina platensis, Coriandrum sativum, Allium sativum, Curcuma longa, Silybum marianum, Rehmannia glutinosa, Phyllanthus amarus, Orthosiphon stamineus, Triphala, Brassica juncea, Moringa oleifera, and Curcuma zedoaria. This is a recovery-support complex, not a specific antidote to neomycin and not a substitute for hemodialysis in severe intoxication.

Given the nephrotoxicity of neomycin, renal support is a priority, but it should not be reduced to uncontrolled stimulation of urine output. Orthosiphon stamineus may be considered when renal filtration is preserved, blood pressure is stable, and there is no dehydration. In oliguria, rising creatinine, hypotension, or electrolyte disturbances, diuretic herbal therapy without prior assessment may worsen the condition.

For metabolic and antioxidant support, Silybum marianum, Phyllanthus amarus, Phyllanthus emblica, and Curcuma longa may be used. Neomycin is eliminated primarily by the kidneys and does not automatically require “liver treatment” simply because it has been used. These products are appropriate when there is a relevant metabolic, inflammatory, or antioxidant objective rather than as an automatic regimen for every patient.

After an oral course, protecting the intestinal barrier is important. Colostrum may be used as part of a recovery approach for mucosal tissues and local immune defense if there is no allergy to cow’s milk proteins or intolerance to its components. Centella asiatica may be included in a reparative approach. Persistent diarrhea, steatorrhea, blood in the stool, severe pain, or weight loss require diagnostic evaluation rather than masking of symptoms.

Polypore mushroom extract and Phyllanthus emblica may be used as additional general restorative and antioxidant support. Boswellia serrata is more appropriate when a systemic or local inflammatory component persists. Hericium erinaceus extract may be considered for neuropathic complaints and as part of a nervous-system recovery program, but it should not be presented as a treatment capable of regenerating destroyed hair cells of the inner ear.

In practice, the program should not be based on prescribing all of the listed products simultaneously, but on the targets identified in the individual patient. A basic approach includes discontinuing an unnecessary antibiotic, monitoring creatinine, estimated filtration, urinalysis, and hearing, restoring hydration, using the Metal and Xenobiotic Detoxification Complex, supporting the intestinal barrier, and selecting additional botanical products according to the clinical objective. Attempting to take ten products at once turns recovery from polypharmacy into a new episode of polypharmacy.

In diseases of the upper respiratory tract and external ear, preventing repeated unjustified prescribing of neomycin is a separate objective. ABP-153 may be considered as a topical integrative alternative in selected uncomplicated inflammatory, fungal, allergic, and mixed conditions of the nasal mucosa and external auditory canal when a systemic antibiotic is not required. Before any product is introduced into the ear, the integrity of the tympanic membrane must be confirmed.

For rhinitis and rhinosinusitis, ABP-153 may be combined with the “Rhinitis and Rhinosinusitis” complex. When an allergic component is present, “Allergy Mixture”, Nigella sativa, and Scutellaria baicalensis may be considered. In bronchial hyperreactivity, Clerodendrum serratum or “Bronchial Asthma Type 2” may be included in the regimen.

Complete replacement of an antibiotic is acceptable only when there is no proven severe bacterial process. Purulent otitis media, mastoiditis, severe bacterial sinusitis, high fever, systemic intoxication, or orbital or intracranial complications require appropriate antibacterial therapy selected according to the diagnosis, site of infection, and suspected pathogen.

The actual effectiveness of neomycin and medical errors

Neomycin is a bactericidal aminoglycoside. It binds to the 30S subunit of the bacterial ribosome, disrupts the accuracy of translation, and interferes with protein synthesis. The oral form is poorly absorbed and acts primarily within the intestinal lumen. Official indications include suppression of intestinal bacterial flora before bowel surgery and use as an adjunctive treatment for hepatic encephalopathy.

Neomycin is not intended for systemic treatment of common respiratory tract, middle-ear, or urinary tract infections or sepsis: poor absorption makes the oral form ineffective for these purposes, while toxicity limits parenteral use.

Topical formulations may be effective for superficial infections of the skin, eye, or external auditory canal caused by susceptible bacteria. The otic combination of neomycin with polymyxin B covers a number of Gram-negative bacteria and Staphylococcus aureus, but it has insufficient activity against streptococci, including Streptococcus pneumoniae. It does not treat viral, fungal, or allergic conditions.

Combination with a corticosteroid rapidly reduces inflammation, itching, and redness, but this does not always mean that the underlying cause of the disease has been eliminated. A corticosteroid may mask a fungal infection, contact dermatitis, or a persistent bacterial process. Temporary improvement after using drops does not confirm that the diagnosis is correct.

Medical errors include prescribing ear drops without otoscopy, using neomycin for suspected otomycosis or allergic or eczematous inflammation, continuing treatment for more than ten days, repeating courses without culture testing, failing to assess hearing and renal function, prescribing the drug to a patient with pre-existing tinnitus without documenting baseline status, and combining it with other nephrotoxic and ototoxic drugs.

Another error is prescribing oral neomycin for ordinary diarrhea, “dysbiosis,” or prophylactic “intestinal disinfection.” Without a confirmed indication, such therapy does not provide the expected benefit but retains the risks of malabsorption, organ toxicity, superinfection, and antibiotic resistance.

Safety monitoring during treatment

Before oral neomycin is started, serum creatinine, urea, electrolytes, estimated glomerular filtration rate or creatinine clearance, and urinalysis should be assessed. Urine should be monitored for protein, casts, cells, and specific gravity. During a prolonged course or in the presence of risk factors, these tests should be repeated over time.

In patients with pre-existing tinnitus, hearing loss, balance impairment, advanced age, renal dysfunction, or repeated aminoglycoside exposure, baseline and follow-up audiometry are necessary. High-frequency testing is preferable because toxic injury begins above the usual speech-frequency range.

New tinnitus, deterioration of hearing, dizziness, unsteadiness, or oscillopsia are grounds for immediate discontinuation of the drug. Subjectively normal hearing does not exclude early ototoxicity.

An increase in creatinine, a decline in estimated filtration, protein or casts in the urine, or reduced urine output requires discontinuation of therapy and assessment of the degree of renal injury. Continuing treatment in a patient with toxic kidney injury increases the risk of further neomycin accumulation.

With topical use, itching, swelling, scaling, weeping, and the course of healing should be assessed daily. Increased inflammation or lack of improvement may indicate sensitization, resistance of the pathogen, or an incorrect diagnosis. If otitis externa does not improve within one week, the official prescribing information recommends repeat microbiological evaluation and reconsideration of treatment.

Emergency warning signs include sudden hearing loss, severe dizziness, inability to stand or walk, a marked decrease in urine output, progressive muscle weakness, impaired swallowing, shortness of breath, and respiratory depression. Waiting and self-treatment worsen the prognosis because cochlear damage may become irreversible and neuromuscular blockade may require mechanical ventilation.

Proper discontinuation of neomycin

Neomycin does not cause physiological dependence and does not require gradual dose reduction. In cases of ototoxicity, nephrotoxicity, neuromuscular blockade, severe diarrhea, or contact sensitization, the drug should be discontinued immediately.

When a bacterial infection has been confirmed, discontinuing neomycin does not mean that the infection should be left untreated. Neomycin should be replaced with a drug appropriate for the site of infection, susceptibility of the pathogen, and the patient’s condition. Independently stopping and then restarting the course is unacceptable.

After discontinuation, hearing and renal function should continue to be monitored. Ototoxicity may become apparent or continue to progress later. The absence of a withdrawal syndrome does not mean that delayed consequences are absent.

In allergic contact dermatitis, neomycin should be excluded from future use. The patient should check the ingredients of ointments and ophthalmic and otic drops because repeated exposure may cause more rapid and pronounced inflammation.

A rational approach to treatment

Neomycin is justified for a narrow range of indications in which its local action genuinely corresponds to an established therapeutic objective. The oral form is used to suppress intestinal flora before surgery and in selected treatment regimens for hepatic encephalopathy. Topical formulations may be used for confirmed superficial bacterial infections caused by susceptible organisms.

The drug should not be used automatically for every inflammatory condition of the skin, nose, ear, or eye. Before prescribing it, the likely nature of the disease should be determined, the tympanic membrane assessed in ear disorders, fungal and allergic processes excluded, concomitant medications reviewed, and renal function checked.

In uncomplicated diseases of the upper respiratory tract and external ear that do not require a systemic antibiotic, ABP-153 and targeted botanical complexes may be considered. The purpose of such substitution is not to reject necessary antibacterial therapy but to prevent unnecessary aminoglycoside exposure, ototoxicity, nephrotoxicity, contact sensitization, and disruption of the microbiota.

After a course has already been completed, a structured detoxification and recovery program becomes central: discontinuation of an unjustified antibiotic, monitoring of hearing and renal function, restoration of hydration, and support of the intestinal barrier, physiological elimination pathways, and antioxidant defenses. The Metal and Xenobiotic Detoxification Complex may serve as the foundation of such a program, but it does not replace emergency treatment of acute renal failure, respiratory blockade, or severe ototoxicity.

If you have questions about the topic of this article, you can ask a clinical pharmacologist in the comments or schedule an appointment using the following link: https://asiabiopharm.com/konsultaciii/